Skip to main content

Table 1 Study participants characteristics (n = 97)

From: The impact of antiretroviral therapy on symptom burden among HIV outpatients with low CD4 count in rural Uganda: nested longitudinal cohort study

Factor   n (%)
Sex Male 30 (31%)
Female 67 (69%)
Age Mean (s.d.) 36 (8)
WHO HIV stage 1 3 (3%)
2 34 (35%)
3 54 (56%)
4 6 (6%)
CD4 cells (cells/ul) <50 22 (23%)
50–99 19 (19%)
100–149 24 (25%)
150–199 32 (33%)
Main study treatment arm Median (IQR) 120 (58–163)
Fluconazole 47 (48%)
Placebo 50 (52%)
Anti-retroviral treatment backbone (missing = 2) AZT/3TC 77 (81%)
D4T/3TC 16 (17%)
Truvada 2 (2%)
Non-nucleoside reverse-transcriptase inhibitors (missing = 1) Nevirapine 70 (73%)
Efavirenz 26 (27%)
Died during study No 88 (91%)
Yes 9 (9%)
  1. AZT zidovudine; 3TC lamivudine; d4T Stavudine; Truvada emtricitabine and tenofovir disoproxil fumarate